Breaking News, Collaborations & Alliances

SpringWorks to Develop Rappta’s First-in-Class Cancer Drug

SpringWorks will be responsible for global development and commercialization of RPT04402, a first-in-class molecular glue of specific PP2A complexes.

Author Image

By: Charlie Sternberg

Associate Editor

Rappta Therapeutics, a private biotech focused on developing anti-cancer drugs activating protein phosphatase 2A (PP2A), has announced an exclusive global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific Protein Phosphatase 2A (PP2A) complexes. Rappta’s PP2A-reactivating technologies have the potential to create a new class of anti-cancer drugs for treating a broad range of human cancers. PP2A is a critical enzyme in regulating pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters